How Does CBD Help with Sleeping Disorders? may provide temporary relief, the relief is brief and often leads to even worse problems. CBD. Of the + different cannabinoids found in cannabis, cannabidiol (CBD) and to the 40 percent of Canadians who live with some form of sleep disorder, according to a study by Treat Sleep Issues with Cannabis. Insomnia, along with other sleep disorders currently affect around 25% of or problems staying asleep, which can be related to poor sleeping.
CBD Sleep for Using About Concerns
In the last half century, modern science has begun to shed light on the biological processes behind the healing, where plant and animal chemistry work in concert. The body of research on cannabidiol, CBD oil benefits , THC, and other cannabinoids has grown exponentially in the past decade. The following brings together the latest scientific studies and stories from patients and doctors with advice on treating specific symptoms.
It also includes dosage suggestions and information on recommended types of cannabinoid-based medicines for the particular condition. A opinion statement from the authors of a study on cannabinoids and gastrointestinal disorders summarizes the current climate and calls for action from the medical community to bring cannabis-based medicine into line with our current understanding of neurochemistry. Despite the political and social controversy affiliated with it, the medical community must come to the realization that cannabinoids exist as a ubiquitous signaling system in many organ systems.
Our understanding of cannabinoids and how they relate not only to homeostasis but also in disease states must be furthered through research, both clinically and in the laboratory. Endogenous created naturally within the body cannabinoids and their receptors are found not just in the brain but also in many organs as well as connective tissue, skin, glands, and immune cells.
The list of CBD oil benefits and health concerns treatable by CBD is so long because these receptors are integral to so many bodily systems. This is also the reason cannabinoids can be used as a general preventative medicine, protecting the body against the damages of stress and aging.
Cannabinoid therapy is connected to the part of the biological matrix where body and brain meet. Since CBD cannabidiol and other compounds in cannabis are so similar to the chemicals created by our own bodies, they are integrated better than many synthetic drugs.
According to Bradley E. By understanding this system, we begin to see a mechanism that could connect brain activity and states of physical health and disease. Reduced Risk of Diabetes and Obesity Several studies have shown that regular cannabis users have a lower body mass index, smaller waist circumferences, and reduced risk of diabetes and obesity.
One report published in the American Journal of Epidemiology , based on a survey of more than fifty-two thousand participants, concluded that rates of obesity are about one-third lower among cannabis users.
CBD on its own was shown in to lower the incidence of diabetes in lab rats,[ ] and in an Israeli-American biopharmaceutical collective began stage 2 trials related to using CBD to treat diabetes. Respondents who had used cannabis in their lifetime but were not current users showed similar but less pronounced associations, indicating that the protective effect of cannabis fades with time.
The research emerging about the interplay between cannabinoids and insulin regulation may lead to some major breakthroughs in the prevention of obesity and type 2 diabetes. A study that measured data from 4, participants on the effect of cannabis on metabolic systems compared non-users to current and former users. Linked to diet and lifestyle, atherosclerosis is common in developed Western nations and can lead to heart disease or stroke.
It is a chronic inflammatory disorder involving the progressive depositing of atherosclerotic plaques immune cells carrying oxidized LDL or low-density lipoproteins. A growing body of evidence suggests that endocannabinoid signaling plays a critical role in the pathology of atherogenesis.
Studies have demonstrated that inflammatory molecules stimulate the cycle leading to atherosclerotic lesions. The CB2 receptor is also stimulated by plant-based cannabinoids. Reduced Risk of Cancer Could cannabidiol help prevent tumors and other cancers before they grow?
A study showed that animals treated with CBD were significantly less likely to develop colon cancer after being induced with carcinogens in a laboratory. Continuing research is focused on the best ratio of CBD to THC and the most effective dose level in cancer prevention and treatment.
Cannabinoids are neuroprotective, meaning that they help maintain and regulate brain health. The effects appear to be related to several actions they have on the brain, including the removal of damaged cells and the improved efficiency of mitochondria. Extra glutamate, which stimulates nerve cells in the brain to fire, causes cells to become over-stimulated, ultimately leading to cell damage or death. Thus, cannabinoids help protect brain cells from damage, keeping the organ healthy and functioning properly.
CBD has also been shown to have an anti-inflammatory effect on the brain. As the brain ages, the creation of new neurons slows down significantly. In order to maintain brain health and prevent degenerative diseases, new cells need to be continuously created. A study showed that low doses of CBD- and THC-like cannabinoids encouraged the creation of new nerve cells in animal models, even in aging brains. Cannabinoids are facilitative of the process of bone metabolism—the cycle in which old bone material is replaced by new at a rate of about 10 percent per year, crucial to maintaining strong, healthy bones over time.
CBD in particular has been shown to block an enzyme that destroys bone-building compounds in the body, reducing the risk of age-related bone diseases like osteoporosis and osteoarthritis. In both of those diseases, the body is no longer creating new bone and cartilage cells.
CBD helps spur the process of new bone-cell formation, which is why it has been found to speed the healing of broken bones and, due to a stronger fracture callus, decrease the likelihood of re-fracturing the bone bones are 35—50 percent stronger than those of non-treated subjects.
Protects and Heals the Skin The skin has the highest amount and concentration of CB2 receptors in the body. When applied topically as an infused lotion, serum, oil, or salve, the antioxidant a more powerful antioxidant than vitamins E and C  in CBD oil has many benefits and can repair damage from free radicals like UV rays and environmental pollutants. Cannabinoid receptors can be found in the skin and seem to be connected to the regulation of oil production in the sebaceous glands.
In fact, historical documents show that cannabis preparations have been used for wound healing in both animals and people in a range of cultures spanning the globe and going back thousands of years. The use of concentrated cannabis and CBD oils to benefit and treat skin cancer is gaining popularity with a number of well-documented cases of people curing both melanoma and carcinoma-type skin cancers with the topical application of CBD and THC products.
Best known is the case of Rick Simpson, who cured his basal cell carcinoma with cannabis oil and now has a widely distributed line of products. Cannabis applied topically is not psychoactive.
Cannabinoids have been proven to have an anti-inflammatory effect in numerous studies. CBD engages with the endocannabinoid system in many organs throughout the body, helping to reduce inflammation systemically. The therapeutic potential is impressively wide-ranging, as inflammation is involved in a broad spectrum of diseases. The oral use of cannabis and CBD for anxiety appears in a Vedic text dated around BCE, and it is one of the most common uses of the plant across various cultures.
While THC can increase anxiety in some patients, it lowers it in others. However, CBD effects have been shown to consistently reduce anxiety when present in higher concentrations in the cannabis plant. On its own, CBD has been shown in a number of animal and human studies to lessen anxiety. The stress-reducing effect appears to be related to activity in both the limbic and paralimbic brain areas. A research review assessed a number of international studies and concluded that CBD has been shown to reduce anxiety , and in particular social anxiety, in multiple studies and called for more clinical trials.
It is suggested that patients work with a health care practitioner experienced in recommending cannabidiol or medicinal cannabis so that dosage and delivery methods can be developed and fine-tuned on an individual basis. At the same time, educated and aware patients can be their own highly informed health consultants.
For anxiety, CBD products with a ratio of High-CBD cannabinoids can be very effective in reducing chronic anxiety, treating temporary stress, and protecting the body from the physiological effects of both. Varieties high in linalool, a terpene shared with lavender, are known to be effective for relieving anxiety.
Always start with the micro dose to test sensitivity and go up as needed within the dosing range, before going to the next, until symptoms subside. The micro to standard dose is usually recommended to treat stress and anxiety with CBD. For relief of immediate symptoms, as in a panic or anxiety attack, vaporizing or smoking work well. The medication lasts one to three hours, whereas most ingested products, including CBD oil, take thirty to sixty minutes before taking effect and last six to eight hours.
Herbal vaporizers that use the whole plant are also an effective delivery method. Sublingual sprays or tinctures taken as liquid drops take effect quickly and last longer than inhaled products. The Cannabis Health Index CHI is an evidence-based scoring system for cannabis in general, not just CBD oil effects and its effectiveness on various health issues based on currently available research data.
Using this rubric and based on eleven studies, cannabis rated in the possible-to-probable range of efficacy for treatment of anxiety. Elixinol Organic High Potency CBD Capsules Elixinol offers a highly concentrated, high-potency, organic whole-hemp plant CBD oil , which is naturally extracted with carbon dioxide and free of all synthetics and chemicals.
Whole-hemp plant extracts contain synergistic compounds that are believed to enhance the effectiveness and benefits of CBD. Clinical depression is a serious mood disorder characterized by persistent sadness and loss of interest, sometimes leading to decreased appetite and energy and suicidal thoughts. Commonly used pharmaceuticals for depression often target serotonin, a chemical messenger that is believed to act as a mood stabilizer.
The neural network of the endocannabinoid system works similarly to the way that serotonin, dopamine, and other systems do, and, according to some research, cannabinoids have an effect on serotonin levels. Whereas a low dose of THC increases serotonin, high doses cause a decrease that could worsen the condition. CBD products with a ratio of Specifically, products made with Valentine X or Electra 4 are more energizing, helping relieve depression. When low energy is an issue, sativa or other stimulating strains can be helpful for improving energy and focus when THC can be tolerated.
Varieties that are high in the terpene limonene are recommended for mood elevation. Always start with the micro dose to test sensitivity and go up as needed within the dosing range before going to the next, until symptoms subside. The micro to standard dose is usually recommended to treat depression. Vaporized or smoked cannabis is recommended for relief of immediate symptoms, or a boost in dosage, and it can also be useful for sleep issues.
Selection for the case series was contingent on informed consent to be treated with CBD for 1 of these 2 disorders and at least 1 month of active treatment with CBD. Patients treated with CBD were provided with psychiatric care and medications as usual. Most patients continued to receive their psychiatric medications. The patient population mirrored the clinic population at large with the exception that it was younger. If anxiety complaints predominated, the dosing was every morning, after breakfast.
If sleep complaints predominated, the dosing was every evening, after dinner. Often CBD was employed as a method to avoid or to reduce psychiatric medications. Informed consent was obtained for each patient who was treated and considered for this study. CBD was added to care, dropped from care, or refused as per individual patient and practitioner preference.
Wholeness Center is a large mental health clinic in Fort Collins, CO, that focuses on integrative medicine and psychiatry. Practitioners from a range of disciplines psychiatry, naturopathy, acupuncture, neurofeedback, yoga, etc work together in a collaborative and cross-disciplinary environment.
CBD had been widely incorporated into clinical care at Wholeness Center a few years before this study, on the basis of existing research and patient experience. The sampling frame consisted of adult patients who were consecutively treated with CBD at our psychiatric outpatient clinic.
Patients with sole or primary diagnoses of schizophrenia, posttraumatic stress disorder, and agitated depression were excluded. Ten patients were further excluded because they had only 1 documented visit, with no follow-up assessment.
The final sample consisted of 72 adult patients presenting with primary concerns of anxiety Sleep and anxiety were the targets of this descriptive report. Sleep concerns were tracked at monthly visits using the Pittsburg Sleep Quality Index.
Anxiety levels were monitored at monthly visits using the Hamilton Anxiety Rating Scale. Both scales are nonproprietary. The Hamilton Anxiety Rating Scale is a widely used and validated anxiety measure with 14 individual questions. It was first used in and covers a wide range of anxiety-related concerns. The score ranges from 0 to A score under 17 indicates mild anxiety, and a score above 25 indicates severe anxiety.
The Pittsburg Sleep Quality Index is a self-report measure that assesses the quality of sleep during a 1-month period. It consists of 19 items that have been found to be reliable and valid in the assessment of a range of sleep-related problems. Each item is rated 0 to 3 and yields a total score from 0 to A higher number indicates more sleep-related concerns. Side effects and tolerability of CBD treatment were assessed through spontaneous patient self-reports and were documented in case records.
Any other spontaneous comments or complaints of patients were also documented in case records and included in this analysis. Deidentified patient data were evaluated using descriptive statistics and plotted graphically for visual analysis and interpretation of trends. Most patients with an anxiety diagnosis were men All 72 patients completed sleep and anxiety assessments at the onset of CBD treatment and at the first monthly follow-up.
By the second monthly follow-up, 41 patients On average, anxiety and sleep improved for most patients, and these improvements were sustained over time. At the first monthly assessment after the start of CBD treatment, Two months after the start of CBD treatment, These results demonstrated a more sustained response to anxiety than for sleep over time.
Patient records displayed a larger decrease in anxiety scores than in sleep scores. The sleep scores demonstrated mild improvement. The anxiety scores decreased within the first month and then remained decreased during the study duration.
CBD was well tolerated, with few patients reporting side effects. Two patients discontinued treatment within the first week because of fatigue. Three patients noted mild sedation initially that appeared to abate in the first few weeks. One patient with a developmental disorder aged 21 years had to be taken off the CBD regimen because of increased sexually inappropriate behavior. The CBD was held, and the behavior disappeared. The behavior reappeared on redosing 2 weeks later, and the CBD regimen was formally discontinued.
One patient noted dry eyes. Reasons for patients not following-up at later assessment points are largely unknown but are probably because of standard attrition experienced in usual clinical practice.
There was no evidence to suggest patients discontinued care because of tolerability concerns. The attrition rates were similar in nature and size to those found in routinely scheduled visits in this clinic.
Four patients declined CBD treatment because of religious or ethical concerns about the relation to cannabis. Nearly all patients easily provided informed consent once the nature of the treatment was explained. Most patients appreciated the opportunity to try something natural and avoid further or initial psychiatric medication use.
In an outpatient psychiatric population, sleep scores displayed no sustained improvements during the 3-month study. Anxiety scores decreased fairly rapidly, and this decrease was sustained during the study period. These results are consistent with the existing preclinical and clinical data on CBD. CBD was well accepted and well tolerated in our patients.
Side effects were minimal mainly fatigue and may be related to dosing. The first is that in our experience lower doses appear to elicit an adequate clinical response. These results must be interpreted cautiously because this was a naturalistic study, all patients were receiving open-label treatment, and there was no comparison group.
Concurrent psychiatric medications were employed as in routine clinical care. This is both a limitation and strength, as very few publications exist in this population. Other researchers have noted that the large societal notoriety about cannabis and medical marijuana probably contributes to a larger-than-normal placebo effect.
Likewise, the clinical population in this case series is skewed younger than typical for our clinic, and future studies could explore the possible selection bias inherent in this treatment option. Most patients were also taking psychiatric medications and receiving other mental health services, such as counseling, which limits the ability to make any causal links to CBD treatment.
Clinical attrition is evident in the dataset. The reason for this might be related to CBD ingestion or not, so the overall component remains unclear. Furthermore, patients at our clinic often express a desire to reduce or to avoid use of psychiatric medications, which may contribute to an enhanced placebo effect or additional bias. The length of clinical monitoring may help to decrease this concern.
However, the clinical data in this analysis show a trend toward clinically significant relief of anxiety upon the start of CBD treatment. The legality of CBD is not clear. Like the issues surrounding the legality of cannabis in general, CBD presents the clinician with a confusing state vs federal legal quandary, and this keeps the issue in question. The federal government has announced that it is not focused on this compound in terms of enforcement or interdiction.
Pending federal legislation to redefine the legal status of cannabis would clarify this complex issue. Formal studies on efficacy and dose finding are much needed. Some urgency exists, given the explosion of lay interest in this topic and the rush to market these compounds. Current understanding of the physiology and neurologic pathways points to a benefit with anxiety-related issues. The results of our clinical report support the existing scientific evidence.
In our study, we saw no evidence of a safety issue that would limit future studies. In this evaluation, CBD appears to be better tolerated than routine psychiatric medications. Furthermore, CBD displays promise as a tool for reducing anxiety in clinical populations, but given the open-label and nonrandomized nature of this large case series, all results must be interpreted very cautiously. Randomized and controlled trials are needed to provide definitive clinical guidance.
Dr Shannon has published several professional books on integrative mental health. Dr Shannon is a Principal Investigator for a Phase 3 study of 3,4-methylenedioxy-methamphetamine MDMA -assisted psychotherapy for severe posttraumatic stress disorder and receives compensation for his clinical work from the Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA. The other authors have no conflicts of interests to disclose. CV Sciences was not involved in the data collection, data interpretation, preparation of the report, or decision to submit the report for publication.
No other financial support was provided. The authors would like to express their deep appreciation to the staff and clinicians at Wholeness Center for their professionalism. Cannabidiol in anxiety and sleep: A large case series. Original Research and Contributions. You will receive an Email notice with the Table of Contents of each issue.
CBD for Sleep: Sweet Dreams with CBD Oil
Only one purported use for cannabidiol, to treat epilepsy, has significant antidepressant or sleep aid "have all been studied in animals, with only one or two There also are concerns about both the quality of CBD oil being. With CBD oil, there is no risk of intoxication (getting high) , so much of using herbal cannabis worry about the stigma associated with the typical multiple sclerosis, chronic pain), and even pets (anxiety, appetite, sleep). It's also said that CBD oil can promote sounder sleep, reduce inflammation and pain, There's also some concern that the use of CBD oil may lead to increased .